U.S. Contraceptive Drugs And Devices Market Analysis & Forecast: 2026-2033

U.S. Contraceptive Drugs and Devices Market Size and Share Analysis: (2026 – 2033)

The U.S. contraceptive drugs and devices market size is projected to grow from approximately USD 11,770.0 Mn in 2026 to USD 17,330.9 Mn by 2033, registering a compound annual growth rate (CAGR) of 5.6% during the forecast period (2026–2033). This growth is driven by increasing awareness of reproductive health, rising adoption of modern contraceptive methods, supportive government family planning initiatives, and continuous innovation in hormonal and non-hormonal contraceptive products and devices.

Key Takeaways from the U.S. Contraceptive Drugs and Devices Market Report

• The Devices segment is projected to dominate the overall market with about 55% market share in 2026 due to increased use of long-acting reversible contraception (LARC) methods like IUDs, implantable, and vaginal rings. The market is supported by clinical studies, which show that LARC methods have a 99% success rate in avoiding pregnancy.

Segmental Insights

To learn more about this report, Request Free Sample

Why is the Devices Segment Acquiring the Largest Market Share in the U.S. Contraceptive Market?

The devices segment is forecast to hold the highest market share in the United States contraceptive drugs and devices market during 2026, accounting for about 55% of the total market value. The dominance of the segment can be attributed mainly to growing popularity of long-acting reversible contraception (LARC) devices like IUDs, subcutaneous implants, and hormonal vaginal rings.

Such rapid growth is driven by the structural change in consumers' preferences from short-term contraceptive methods such as birth control pills to long-term, maintenance-free contraceptives with better efficacy and convenience.

For instance, according to the CDC, about 64% of American women aged between 15 and 49 years use contraceptive methods, indicating a robust and consistent consumer base for pharmaceutical as well as mechanical contraceptives.

In February 2026, Organon announced that it has entered into an exclusive global licensing agreement with Sebela Pharmaceuticals to commercialize MIUDELLA, a hormone-free copper intrauterine device (IUD).

Growing preference for low-maintenance, long-duration contraception is reducing reliance on daily oral pills

Oral contraceptives need high levels of commitment, whereas implants and intrauterine devices offer long-term protection (3-10 years or more based on type). This convenience is contributing to a shift away from oral contraceptives toward long-acting devices (which has a 45 percent share in 2026) towards devices.

Government and public health initiatives promoting family planning and reproductive health access

Contraceptive programs sponsored by institutions like WHO and national health departments aim at increasing access to modern contraceptives, with the primary goal of reducing unintended pregnancies and improving maternal health status. These programs improve awareness and adoption of modern contraceptives.

Increasing focus on women’s health awareness and delayed childbirth trends in developed markets

There is an increasing trend among women in the United States to postpone conception in favor of pursuing educational and occupational opportunities, creating an increased need for more reliable and permanent forms of contraception, including intrauterine devices and contraceptive implants.

Current Events and Their Impact on the U.S. Contraceptive Drugs and Devices Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

U.S. Contraceptive Drugs and Devices Market Trends

• The growing popularity of long-term contraception devices like IUDs and implants: The trend of using highly reliable and easy-to-use contraception has led many women to use devices rather than relying on pills.
• Increased accessibility due to insurance policies and preventive health services: According to the Affordable Care Act, the majority of health insurance plans in the United States must cover all FDA-approved contraceptive drugs and devices at zero cost.
• Increased use of telemedicine for contraception prescriptions and counseling: With advancements in telemedicine and digital healthcare technologies, the provision of contraceptive drugs has increased, especially in rural settings. This has led to stable demand in the drug category.
• Increased emphasis on women's health and delayed childbearing trends: Many women have been putting off having children until later in life, either due to educational pursuits or careers.
• Strong public health support for family planning and reproductive health access:
  Organizations like the WHO emphasize contraception access as a key factor in reducing unintended pregnancies and improving maternal health outcomes globally.

Who are the Major Companies in U.S. Contraceptive Drugs and Devices Industry

Some of the major key players in U.S. Contraceptive Drugs and Devices are Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Merck & Co. Inc., Allergan Plc, Cooper Surgical, Inc., Cipla Limited, HLL Lifecare.

Industry News

• In February 2026, Organon announced a global licensing agreement with Sebela Pharmaceuticals to commercialize MIUDELLA, expanding access to the copper IUD in international markets, including the U.S. rollout preparations.
• In January 2025, NEXT Life Sciences received a $200,000 funding installment from the Male Contraceptive Initiative (MCI) as part of a two-year $400,000 grant program supporting development of its Plan A™ hydrogel-based male contraceptive system.

Market Report Scope

Analyst Opinion

• The U.S. contraceptive market is shifting from oral contraceptives toward LARC-based devices because of greater efficiency and convenience (greater than 99% efficacy rate).
• The future of contraception will depend on IUDs, subdermal implants, and new non-pharmaceutical contraceptives.
• The market will witness an increase in the availability of long-lasting contraceptives and better-quality device materials, thereby minimizing the frequency of their replacement.
• Telemedicine and digital health platforms have been facilitating greater access to contraceptive prescription and counseling, particularly oral contraceptives.
• Opportunity for growth can be seen in the long-term device market including implants and IUDs because of their low maintenance and high efficacy.
• Although pills are likely to continue to be significant, they will experience slow growth compared to devices owing to telehealth and OTC access.
• Despite any problems, the availability of insurance coverages (ACA), public health programs, and reproductive health education will ensure future success of the market.
• Overall, the market is expected to transition to an innovation-based environment driven by technology and centered on digital health care solutions.

Market Segmentation

• By Product Type (Revenue, USD Mn, 2021-2033)
  • Drugs
    • Oral Contraceptive Pills
    • Contraceptive Injectables
    • Topical Contraceptives
  • Devices
    • Male Devices
      • Condoms
    • Female Devices
      • Condoms
      • Contraceptive Diaphragms
      • Contraceptive Sponges
      • Contraceptive Vaginal Rings
      • Intrauterine Devices
        • Hormonal
        • Copper-T
      • Subdermal Contraceptive Implants
• Key Players
  • Teva Pharmaceutical Industries Ltd.
  • Church & Dwight Co. Inc.
  • Pfizer, Inc.
  • Bayer AG
  • Mayer Laboratories, Inc.
  • The Female Health Company
  • Merck & Co. Inc.
  • Allergan Plc
  • Cooper Surgical, Inc.
  • Cipla Limited
  •  HLL Lifecare

Sources

Primary Research Interviews

• Chief Medical Officers / Gynecologists / Obstetricians – contraceptive prescribing patterns, LARC adoption, and patient compliance trends (U.S. hospitals & women’s health clinics)
• Directors – Reproductive Health / Family Planning Departments (health systems, public health organizations, and Planned Parenthood centers)
• Clinical Specialists – Obstetrics & Gynecology specialists (IUDs, implants, oral contraceptive usage trends and safety insights)
• Pharmacists – retail and hospital pharmacy dispensing patterns for oral contraceptives and emergency contraception
• Women’s Health & Public Health Experts – reproductive health behavior, awareness, and demographic trends
• Medical Device Specialists – IUDs, implants, vaginal rings, and contraceptive device performance insights

Stakeholders

• Contraceptive Drug Manufacturers
• Medical Device Manufacturers (IUDs, implants, condoms, vaginal rings)
• Pharmaceutical Distributors & Pharmacy Chains
• Hospitals, Gynecology Clinics & Women’s Health Centers
• Public Health Organizations (family planning programs)
• Telehealth & Digital Health Providers (online contraceptive prescriptions and consultations)

End-use Sectors

• Hospitals (Obstetrics & Gynecology departments)
• Specialty Clinics / Women’s Health Clinics
• Ambulatory Care Centers
• Retail Pharmacies & Online Pharmacies
• Family Planning Clinics / Public Health Clinics
• Home Healthcare & Telehealth Platforms

Regulatory & Health Bodies

• U.S. Food and Drug Administration (FDA) – contraceptive drug approvals, device safety, and regulatory oversight
• Centers for Medicare & Medicaid Services (CMS) – insurance coverage under preventive care mandates (ACA-linked contraceptive coverage)
• Centers for Disease Control and Prevention (CDC) – contraceptive prevalence data, reproductive health statistics, and National Survey of Family Growth (NSFG)
• Office of Population Affairs (OPA) – Title X family planning program guidelines and funding
• National Institutes of Health (NIH) – reproductive health and contraceptive innovation research
• World Health Organization (WHO) – global contraceptive guidelines and family planning standards

Databases

• National Survey of Family Growth (NSFG) – contraceptive usage patterns in the U.S.
• CDC Wonder Database – reproductive health and population data
• National Center for Health Statistics (NCHS) – fertility rates and contraceptive prevalence
• ClinicalTrials.gov – ongoing contraceptive drug and device clinical trials
• FDA Device & Drug Databases – approvals, safety updates, and product lifecycle data
• Healthcare Cost and Utilization Project (HCUP) – reproductive health procedures and
• healthcare utilization

Magazines

• Fierce Pharma – contraceptive drug approvals, partnerships, and market activity
• Fierce Healthcare – insurance coverage and reproductive health policy developments
• MedTech Dive – innovations in IUDs, implants, and contraceptive devices
• Pharmaceutical Technology – drug delivery innovations and hormonal contraceptive developments
• STAT News – reproductive health policy and access-related developments
• Endpoints News – biotech and women’s health pipeline updates

Journals

• Contraception (Elsevier) – clinical studies on contraceptive efficacy and safety
• The Lancet Public Health – reproductive health and global contraceptive research
• American Journal of Obstetrics & Gynecology (AJOG) – clinical evidence and OBGYN guidelines
• BMJ Sexual & Reproductive Health – contraceptive effectiveness and policy studies
• Journal of Women’s Health – women’s health outcomes and contraceptive usage behavior
• New England Journal of Medicine (NEJM) – high-impact contraceptive and reproductive health research

Newspapers

• The Wall Street Journal – contraceptive policy, insurance coverage, and pharmaceutical market developments
• The New York Times – reproductive health access, contraceptive policy debates, and women’s health trends
• Washington Post – healthcare policy and contraceptive coverage under ACA
• USA Today – consumer awareness and contraceptive access trends
• Los Angeles Times – reproductive health policy and state-level contraceptive access updates
• Bloomberg – pharmaceutical industry developments and market trends

Associations

• American College of Obstetricians and Gynecologists (ACOG)
• Society for Family Planning (SFP)
• Planned Parenthood Federation of America (PPFA)
• Guttmacher Institute
• American Public Health Association (APHA)
• Association of Reproductive Health Professionals (ARHP)

Public Domain Sources

• U.S. Food and Drug Administration (FDA) – contraceptive drug and device approvals and safety communications
• Centers for Disease Control and Prevention (CDC) – contraceptive prevalence and reproductive health statistics
• National Institutes of Health (NIH) – reproductive health and contraceptive innovation research
• Office of Population Affairs (OPA) – Title X family planning program data
• U.S. Census Bureau – demographic and fertility trend data
• World Health Organization (WHO) – global reproductive health guidelines and reports

Proprietary Elements

• CMI Market Intelligence Database
• CMI Market Repository (10+ years of U.S. reproductive health market tracking)